Novavax delays U.S. trial of Covid-19 vaccine candidate to November

Novavax on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process. Data from an early-to-mid stage or phase 2 trial of the vaccine is now expected on Friday, the company said. Early-stage data had showed the vaccine produced high levels of antibodies against the novel coronavirus.